4.6 Article

Regional hyperperfusion in older adults with objectively-defined subtle cognitive decline

Journal

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
Volume 41, Issue 5, Pages 1001-1012

Publisher

SAGE PUBLICATIONS INC
DOI: 10.1177/0271678X20935171

Keywords

Alzheimer's disease; cerebral blood flow; early detection; mild cognitive impairment; subtle cognitive decline

Funding

  1. U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service [2 1IK2CX001865, 1IK2CX000938, 1IK2CX001415, 1I01CX001842, 5I01CX000565]
  2. NIH [R01 AG049810, R01 AG054049]
  3. Alzheimer's Association [AARF-17-528918, AARG-18-566254, AARG-17-500358]
  4. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  5. DOD ADNI (Department of Defense) [W81XWH-12-20012]
  6. National Institute on Aging
  7. National Institute of Biomedical Imaging and Bioengineering
  8. AbbVie
  9. Alzheimer's Association
  10. Alzheimer's Drug Discovery Foundation
  11. Araclon Biotech
  12. BioClinica, Inc.
  13. Biogen
  14. Bristol-Myers Squibb Company
  15. CereSpir, Inc.
  16. Cogstate
  17. Eisai Inc.
  18. Elan Pharmaceuticals, Inc.
  19. Eli Lilly and Company
  20. EuroImmun
  21. F. Hoffmann-La Roche Ltd
  22. Genentech, Inc.
  23. Fujirebio
  24. GE Healthcare
  25. IXICO Ltd.
  26. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  27. Johnson & Johnson Pharmaceutical Research & Development LLC.
  28. Lumosity
  29. Lundbeck
  30. Merck Co., Inc.
  31. Meso Scale Diagnostics, LLC.
  32. NeuroRx Research
  33. Neurotrack Technologies
  34. Novartis Pharmaceuticals Corporation
  35. Pfizer Inc.
  36. Piramal Imaging
  37. Servier
  38. Takeda Pharmaceutical Company
  39. Transition Therapeutics
  40. Canadian Institutes of Health Research

Ask authors/readers for more resources

The study examined patterns of regional cerebral blood flow across different stages of Alzheimer's disease, revealing increased blood flow in specific brain regions in participants with subtle cognitive decline, potentially reflecting early neurovascular dysregulation and cognitive inefficiencies.
Although cerebral blood flow (CBF) alterations are associated with Alzheimer's disease (AD), CBF patterns across prodromal stages of AD remain unclear. Therefore, we investigated patterns of regional CBF in 162 Alzheimer's Disease Neuroimaging Initiative participants characterized as cognitively unimpaired (CU;n = 80), objectively-defined subtle cognitive decline (Obj-SCD;n = 31), or mild cognitive impairment (MCI;n = 51). Arterial spin labeling MRI quantified regional CBF in a priori regions of interest: hippocampus, inferior temporal gyrus, inferior parietal lobe, medial orbitofrontal cortex, and rostral middle frontal gyrus. Obj-SCD participants had increased hippocampal and inferior parietal CBF relative to CU and MCI participants and increased inferior temporal CBF relative to MCI participants. CU and MCI groups did not differ in hippocampal or inferior parietal CBF, but CU participants had increased inferior temporal CBF relative to MCI participants. There were no CBF group differences in the two frontal regions. Thus, we found an inverted-U pattern of CBF signal across prodromal AD stages in regions susceptible to early AD pathology. Hippocampal and inferior parietal hyperperfusion in Obj-SCD may reflect early neurovascular dysregulation, whereby higher CBF is needed to maintain cognitive functioning relative to MCI participants, yet is also reflective of early cognitive inefficiencies that distinguish Obj-SCD from CU participants.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available